[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100579840":3},{"organization":4,"armGroups":7,"interventions":13,"overallOfficials":19,"centralContacts":34,"locations":42,"responsibleParty":60,"collaborators":10,"id":63,"slug":64,"hasResults":65,"nctId":66,"briefTitle":67,"officialTitle":68,"acronym":10,"eligibilityCriteria":69,"healthyVolunteers":65,"sex":70,"minAge":71,"maxAge":10,"enrollmentInfo":72,"targetDuration":10,"studyType":75,"phases":10,"briefSummary":76,"conditions":77,"keywords":10,"overallStatus":79,"whyStopped":10,"lastUpdateSubmitDate":80,"lastUpdatePostDateStruct":81,"startDateStruct":84,"completionDateStruct":86,"leadSponsor":88,"locationsCount":89},{"fullName":5,"class":6},"Huashan Hospital","OTHER",[8],{"label":9,"type":10,"description":10,"interventionNames":11},"Satralizumab treatment group",null,[12],"Drug: Satralizumab",[14],{"type":15,"name":16,"description":17,"armGroupLabels":18,"otherNames":10},"DRUG","Satralizumab","Satralizumab is the first monoclonal antibody approved for the treatment of NMOSD in China. Currently, there is still a lack of standard patient management pattern for NMOSD. While satralizumab offers the advantage of home administration, there remains a pressing need for optimized patient management.",[9],[20,24,27,30,32],{"name":21,"affiliation":22,"role":23},"Chao Quan, Doctor","Department of Neurology, Huashan Hospital, Shanghai Medical College, Fudan University, Shanghai, People's Republic of China","PRINCIPAL_INVESTIGATOR",{"name":25,"affiliation":22,"role":26},"Qiang Dong, Doctor","STUDY_CHAIR",{"name":28,"affiliation":22,"role":29},"Lei Zhou","STUDY_DIRECTOR",{"name":31,"affiliation":22,"role":29},"Wenjuan Huang, Doctor",{"name":33,"affiliation":22,"role":29},"Jingzi Zhangbao, Doctor",[35,39],{"name":21,"role":36,"phone":37,"phoneExt":10,"email":38},"CONTACT","+8613651957283","chao_quan@fudan.edu.cn",{"name":31,"role":36,"phone":40,"phoneExt":10,"email":41},"+8619921296182","drhuangwenjuan@163.com",[43],{"facility":5,"status":10,"city":44,"state":45,"zip":46,"country":47,"countryCode":48,"cosmosGeoPoint":49,"geoPoint":54,"contacts":55},"Shanghai","Shanghai Municipality","200040","China","CN",{"type":50,"coordinates":51},"Point",[52,53],121.45806,31.22222,{"lat":53,"lon":52},[56],{"name":57,"role":36,"phone":58,"phoneExt":10,"email":59},"Ying Mao","+86 52888828","maoying@fudan.edu.cn",{"type":23,"investigatorFullName":61,"investigatorTitle":62,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"Chao Quan","Professor, Chief Physician","100579840","handle-a-real-world-study-on-satralizumab-in-nmosd-100579840",false,"NCT06829524","HANDLE-a Real World Study on Satralizumab in NMOSD","A Real-World Practical Model of Integrated Management for Chinese Patients with Neuromyelitis Optica Spectrum Disorder (NMOSD) on Satralizumab","Inclusion Criteria:\n\n1. Patients have been diagnosed with NMOSD and tested seropositive for AQP4 antibody, ≥ 12 years old;\n2. EDSS score ≤ 8.5 at baseline;\n3. Patients have experienced ≥ 1 relapse of NMOSD in the last 12 months or ≥ 2 relapses in the last 24 months;\n4. Patients should have received or be anticipated to receive satralizumab treatment for at least 12 months;\n5. Patients understand the study procedures and sign the informed consent form indicating willingness to participate in the study (for those \\\u003C 18 years of age, the guardian should sign the informed consent form on behalf of the patient).\n\nExclusion Criteria:\n\n\\-","ALL","12 Years",{"count":73,"type":74},100,"ESTIMATED","OBSERVATIONAL","This study is a single-center, retrospective-prospective, non-interventional cohort study to assess the clinical outcomes of Chinese NMOSD patients treated with satralizumab in a real-world patient management model by collecting follow-up data in clinical practice.",[78],"Neuromyelitis Optica Spectrum Disorders (NMOSD)","NOT_YET_RECRUITING","2025-03-14",{"date":82,"type":83},"2025-03-18","ACTUAL",{"date":85,"type":74},"2025-03-31",{"date":87,"type":74},"2027-06-30",{"name":5,"class":6},1]